NIAGARA: Bladder-Sparing Potential of Perioperative Immunotherapy

From ESMO 2024, Enrique Grande, MD, PhD, of the MD Anderson Cancer Center Madrid shares his impressions of the important NIAGARA trial investigating perioperative durvalumab for muscle-invasive bladder cancer.

He touches on anticipating change in the perioperative treatment landscape in the next couple of years, whether or not patients are being overtreated with adjuvant therapy, and the vision for bladder-sparing options in the near future.